Matches in SemOpenAlex for { <https://semopenalex.org/work/W2335667890> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W2335667890 endingPage "293" @default.
- W2335667890 startingPage "291" @default.
- W2335667890 abstract "The objective of our study was to determine the maximum tolerable doses (MTDs) of both paclitaxel and cisplatin when given in a weekly schedule alone or simultaneously with G-CSF in advanced solid neoplasms.Patients with advanced cancer either chemotherapy-naive or resistant to standard treatments received paclitaxel in a three-hour infusion followed by cisplatin, with or without the addition of r-HuG-CSF (5 micrograms/kg s.c. days three to five). The starting doses of CDDP and paclitaxel were 25 mg/m2/week and 45 mg/m2/week, respectively. During the first six courses the dosages of the two drugs were alternately escalated by 20% (CDDP = 5 mg/m2/week, and paclitaxel 10 mg/m2/week) at each step until the appearance of dose-limiting toxicity (DLT) in one-third or more of the patients enrolled in that cohort.Fifty-five patients with cancer (16 lung, 16 breast, 11 ovarian, 7 head and neck, 1 renal, 1 esophageal, 1 cervical, 1 soft-tissue sarcoma, and 1 of unknown primary), 25 of whom were pretreated, were entered into the study. A total of 439 weekly courses were delivered. In chemotherapy-naïve patients, the MTDs of cisplatin and paclitaxel were 30 mg/m2/week and 65 mg/m2/week, respectively, in the absence of G-CSF support, which increased to 40 mg/m2/week and 85 mg/m2/week, respectively, when G-CSF was given. There were no toxic deaths in this study. Neutropenia was the main dose-limiting toxicity (100/439 courses), but was seldom severe. Neurotoxicity was quite frequent (18 of 55 patients for the total of 88 courses) but never dose-limiting. It was more frequent and clinically relevant in cisplatin-pretreated patients. Overall 18 patients (eight ovarian, five breast, three lung, and two head and neck) achieved objective responses.The cisplatin-paclitaxel weekly administration seems a safe, practical and effective therapeutical approach in patients with advanced solid neoplasms. Large phase II trials are warranted to accurately define the efficacy of this schedule in cisplatin-paclitaxel sensitive tumors." @default.
- W2335667890 created "2016-06-24" @default.
- W2335667890 creator A5000473694 @default.
- W2335667890 creator A5015849958 @default.
- W2335667890 creator A5019534037 @default.
- W2335667890 creator A5048376385 @default.
- W2335667890 creator A5056559714 @default.
- W2335667890 creator A5069643391 @default.
- W2335667890 creator A5073695437 @default.
- W2335667890 creator A5081605398 @default.
- W2335667890 creator A5082796172 @default.
- W2335667890 date "1997-03-01" @default.
- W2335667890 modified "2023-09-27" @default.
- W2335667890 title "Cisplatin-paclitaxel weekly schedule in advanced solid tumors: A phase I study" @default.
- W2335667890 cites W1836451026 @default.
- W2335667890 cites W1903624192 @default.
- W2335667890 cites W2075960393 @default.
- W2335667890 doi "https://doi.org/10.1023/a:1008248627396" @default.
- W2335667890 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9137800" @default.
- W2335667890 hasPublicationYear "1997" @default.
- W2335667890 type Work @default.
- W2335667890 sameAs 2335667890 @default.
- W2335667890 citedByCount "14" @default.
- W2335667890 countsByYear W23356678902014 @default.
- W2335667890 crossrefType "journal-article" @default.
- W2335667890 hasAuthorship W2335667890A5000473694 @default.
- W2335667890 hasAuthorship W2335667890A5015849958 @default.
- W2335667890 hasAuthorship W2335667890A5019534037 @default.
- W2335667890 hasAuthorship W2335667890A5048376385 @default.
- W2335667890 hasAuthorship W2335667890A5056559714 @default.
- W2335667890 hasAuthorship W2335667890A5069643391 @default.
- W2335667890 hasAuthorship W2335667890A5073695437 @default.
- W2335667890 hasAuthorship W2335667890A5081605398 @default.
- W2335667890 hasAuthorship W2335667890A5082796172 @default.
- W2335667890 hasBestOaLocation W23356678901 @default.
- W2335667890 hasConcept C121608353 @default.
- W2335667890 hasConcept C126322002 @default.
- W2335667890 hasConcept C126894567 @default.
- W2335667890 hasConcept C141071460 @default.
- W2335667890 hasConcept C2776694085 @default.
- W2335667890 hasConcept C2777063308 @default.
- W2335667890 hasConcept C2777292972 @default.
- W2335667890 hasConcept C2778239845 @default.
- W2335667890 hasConcept C2778850193 @default.
- W2335667890 hasConcept C2780427987 @default.
- W2335667890 hasConcept C2781413609 @default.
- W2335667890 hasConcept C29730261 @default.
- W2335667890 hasConcept C71924100 @default.
- W2335667890 hasConcept C90924648 @default.
- W2335667890 hasConceptScore W2335667890C121608353 @default.
- W2335667890 hasConceptScore W2335667890C126322002 @default.
- W2335667890 hasConceptScore W2335667890C126894567 @default.
- W2335667890 hasConceptScore W2335667890C141071460 @default.
- W2335667890 hasConceptScore W2335667890C2776694085 @default.
- W2335667890 hasConceptScore W2335667890C2777063308 @default.
- W2335667890 hasConceptScore W2335667890C2777292972 @default.
- W2335667890 hasConceptScore W2335667890C2778239845 @default.
- W2335667890 hasConceptScore W2335667890C2778850193 @default.
- W2335667890 hasConceptScore W2335667890C2780427987 @default.
- W2335667890 hasConceptScore W2335667890C2781413609 @default.
- W2335667890 hasConceptScore W2335667890C29730261 @default.
- W2335667890 hasConceptScore W2335667890C71924100 @default.
- W2335667890 hasConceptScore W2335667890C90924648 @default.
- W2335667890 hasIssue "3" @default.
- W2335667890 hasLocation W23356678901 @default.
- W2335667890 hasLocation W23356678902 @default.
- W2335667890 hasOpenAccess W2335667890 @default.
- W2335667890 hasPrimaryLocation W23356678901 @default.
- W2335667890 hasRelatedWork W2012575302 @default.
- W2335667890 hasRelatedWork W2020454110 @default.
- W2335667890 hasRelatedWork W2020898191 @default.
- W2335667890 hasRelatedWork W2090905889 @default.
- W2335667890 hasRelatedWork W2154175915 @default.
- W2335667890 hasRelatedWork W2322599439 @default.
- W2335667890 hasRelatedWork W2328421677 @default.
- W2335667890 hasRelatedWork W2354731038 @default.
- W2335667890 hasRelatedWork W2994179340 @default.
- W2335667890 hasRelatedWork W2118693777 @default.
- W2335667890 hasVolume "8" @default.
- W2335667890 isParatext "false" @default.
- W2335667890 isRetracted "false" @default.
- W2335667890 magId "2335667890" @default.
- W2335667890 workType "article" @default.